◼ Archived Business Why the latest heart drug failures should make us all more skeptical of AI hype Two late-stage heart-disease medicines have failed to deliver expected cardiovascular benefits despite promising biomarker improvements, raising questions about how drug developers measure success. 2 sources 2 articles v 1 8d ago
◼ Archived Business Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win Merck KGaA acquires Silence Therapeutics for $1.3 billion following a phase 2 trial win for an siRNA drug. 4 sources 4 articles v 2 28d ago
◼ Archived Business 🔮 fades ✓ AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD AstraZeneca reports positive Phase III trial results for tozorakimab, a drug targeting COPD exacerbations. 2 sources 2 articles v 1 69d ago